Roche’s Columvi combination shows sustained survival benefit at three-year follow up of pivotal phase III STARGLO study: Basel Wednesday, December 10, 2025, 18:00 Hrs [IST] Roch ...

Kiran Mazumdar-Shaw honoured with ‘USC Business Management Award’ for her contributions in global healthcare and biotechnology: Our Bureau, Bengaluru Wednesday, December 10, 2 ...

India to co-host 2nd WHO Global Summit on Traditional Medicine in New Delhi: Our Bureau, New Delhi Wednesday, December 10, 2025, 16:45 Hrs [IST] Union Ministry of Ayush has announ ...

Abbott announces Lingo, an OTC continuous glucose monitor and app, now available on Android devices: Abbott Park, Illinois Wednesday, December 10, 2025, 17:00 Hrs [IST] Abbott ann ...

Zydus and Formycon partner for licensing and supply of biosimilar to Keytruda in US and Canada: Our Bureau, Mumbai Wednesday, December 10, 2025, 15:20 Hrs [IST] Zydus Lifesciences ...

Ceiling Price fixation or revision resulted in annual savings of Rs. 3,800 crore, says minister: Our Bureau, New Delhi Wednesday, December 10, 2025, 15:30 Hrs [IST] The National P ...

Roche introduces new PCR test to help improve diagnostic accuracy for women affected by vaginitis in countries following the CE Mark: Basel Wednesday, December 10, 2025, 15:00 Hrs ...

EpiVax and US FDA scientists publish new insights on immunogenicity risks of peptide-related impurities in generic teriparatide: Providence, Rhode Island Wednesday, December 10, 2 ...

Researchers find genetic basis for important risk factor in blinding eye disease: Bethesda, Maryland Wednesday, December 10, 2025, 15:30 Hrs [IST] A study funded in part by the Na ...

The US Food and Drug Administration (FDA) has approved Omisirge (omidubicel-onlv), the first hematopoietic stem cell transplant (HSCT) therapy to treat patients with severe aplastic anaemia (SAA).

Consistently high efficacy was seen across subgroups with ORR of 96%-100% and three-year ongoing response rates of 60%-83%, including in patients with high-risk characteristics (progression of disease ...

Zydus Lifesciences Ltd., an innovation-led healthcare company, with an international presence has launched ‘Zyrifa’, a denosumab biosimilar. Denosumab is a monoclonal antibody with several indications ...